Recently, Danish biotech company Y-mabs Therapeutics and the US Food and Drug Administration (FDA) concluded a meeting which led to the FDA requiring further data concerning the firm's drug omburtamab.
The US food and drug authority has asked for new data once before – in October, the firm's application was sent back with a demand for more data concerning the production of the drug.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.